UY31809A - Encapsulación de agentes biológicamente activos - Google Patents

Encapsulación de agentes biológicamente activos

Info

Publication number
UY31809A
UY31809A UY0001031809A UY31809A UY31809A UY 31809 A UY31809 A UY 31809A UY 0001031809 A UY0001031809 A UY 0001031809A UY 31809 A UY31809 A UY 31809A UY 31809 A UY31809 A UY 31809A
Authority
UY
Uruguay
Prior art keywords
biologically active
active agents
encapsulation
compositions
vehicles
Prior art date
Application number
UY0001031809A
Other languages
English (en)
Spanish (es)
Inventor
Ian Richard Catchpole
Gerald Wayne Gough
Papanicolaou Irene
Beaton Andrew
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY31809A publication Critical patent/UY31809A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
UY0001031809A 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos UY31809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
UY31809A true UY31809A (es) 2009-12-14

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
UY0001031810A UY31810A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031808A UY31808A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031807A UY31807A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031809A UY31809A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
UY0001031810A UY31810A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031808A UY31808A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos
UY0001031807A UY31807A (es) 2008-05-06 2009-05-05 Encapsulación de agentes biológicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (de)
EP (2) EP2271323A2 (de)
JP (1) JP2011522792A (de)
KR (3) KR20110010758A (de)
AR (4) AR072359A1 (de)
CA (1) CA2721241A1 (de)
CL (4) CL2009001076A1 (de)
PE (4) PE20091965A1 (de)
TW (4) TW201012488A (de)
UY (4) UY31810A (de)
WO (1) WO2009135853A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088963A (zh) * 2008-05-06 2011-06-08 葛兰素集团有限公司 生物活性剂的囊封方法
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
CA2946807A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
CA2946810A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
ES2906726T3 (es) * 2014-06-12 2022-04-20 Adare Pharmaceuticals Usa Inc Composiciones de administración de fármaco de liberación prolongada
EP3160449B1 (de) 2014-06-24 2023-12-13 The Trustees of Princeton University Verfahren zum einkapseln von löslichen biologika, therapeutika und kontrastmitteln
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020056323A1 (en) * 2018-09-13 2020-03-19 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
US6068857A (en) * 1993-09-09 2000-05-30 Schering Aktiengesellchaft Microparticles containing active ingredients, agents containing these microparticles, their use for ultrasound-controlled release of active ingredients, as well as a process for their production
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ530315A (en) * 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
EP1796650B1 (de) 2004-09-14 2009-01-07 NanoDel Technologies GmbH Abgabevehikel mit nanoteilchen
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8227576B2 (en) 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
EP1958957A1 (de) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptid mit einem "Knottin" Proteinteil
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists

Also Published As

Publication number Publication date
KR20110010760A (ko) 2011-02-07
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
TW201012488A (en) 2010-04-01
TW201012490A (en) 2010-04-01
AR071634A1 (es) 2010-06-30
EP2271323A2 (de) 2011-01-12
PE20091829A1 (es) 2009-12-12
CA2721241A1 (en) 2009-11-12
AR072668A1 (es) 2010-09-15
UY31808A (es) 2009-12-14
EP2441447A1 (de) 2012-04-18
CL2009001080A1 (es) 2010-09-24
KR20110015604A (ko) 2011-02-16
UY31807A (es) 2009-12-14
AR071633A1 (es) 2010-06-30
PE20091882A1 (es) 2009-12-24
TW201012489A (en) 2010-04-01
KR20110010758A (ko) 2011-02-07
PE20091965A1 (es) 2010-01-09
CL2009001081A1 (es) 2010-09-24
WO2009135853A3 (en) 2011-05-12
CL2009001076A1 (es) 2010-09-24
JP2011522792A (ja) 2011-08-04
CL2009001077A1 (es) 2010-09-24
US20110064821A1 (en) 2011-03-17
WO2009135853A2 (en) 2009-11-12
UY31810A (es) 2009-12-14
AR072359A1 (es) 2010-08-25

Similar Documents

Publication Publication Date Title
UY31808A (es) Encapsulación de agentes biológicamente activos
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
IN2014DN06529A (de)
NZ719345A (en) Lipid nanoparticle compositions and methods for mrna delivery
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
CO6571886A2 (es) Antagonistas de pcsk9
WO2013122932A3 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
EP2852380A4 (de) Lipidbeschichtete albumin-nanopartikelzusammensetzungen sowie verfahren zur herstellung und verfahren zur verwendung davon
ZA201404483B (en) Improvements in or relating to the encapsulation of perfumes
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
IN2014DN08721A (de)
BRPI0912230A2 (pt) Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica
MX342270B (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
TR201818992T4 (tr) Polimerik Finasterid Nanoparçacık, Bunu İçeren Sulu Bileşim, Alopesi Tedavisine Yönelik Bileşim, Bahsedilen Bileşimi Hazırlamaya Yönelik Metot Ve Bunların Kullanımı
CR20140594A (es) Composiciones farmacéuticas y tratamiento de mastitis
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
PL2753182T3 (pl) Środki czynne przeciw szczepom Pseudomonas powodującym choroby gnilne w uprawach grzybów, ich zastosowanie i zawierające je kompozycje
BR112012026542A2 (pt) abordagem seletiva de tecido
CR20110022A (es) Nuevas posibilidades de lucha contra la giardiasis
IL246448A0 (en) Preparations and methods for transferring active telomerase to cells in vivo
WO2009135854A3 (en) Encapsulation of biologically active agents